Search

Your search keyword '"Perez-Oteyza, Jaime"' showing total 14 results
Start Over Author "Perez-Oteyza, Jaime"
14 results on '"Perez-Oteyza, Jaime"'

1. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients

Author

Martínez-Cuadrón, David, Gil, Cristina, Serrano, Josefina, Rodríguez, Gabriela, Pérez-Oteyza, Jaime, García-Boyero, Raimundo, Jiménez-Bravo, Santiago, Vives, Susana, Vidriales, María Belén, Lavilla, Esperanza, Pérez-Simón, José A., Tormo, Mar, Colorado, Mercedes, Bergua, Juan, López, Juan A., Herrera, Pilar, Hernández-Campo, Pilar, Gorrochategui, Julián, Primo, Daniel, Rojas, Jose Luis, Villoria, Jesús, Moscardó, Federico, Troconiz, Iñaki, Linares Gómez, María, Martínez-López, Joaquín, Ballesteros, Joan, Sanz, Miguel, and Montesinos, Pau

Published
2019
Full Text
View/download PDF

4. Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling withex vivochemosensitivity

Author

Onecha, Esther, primary, Ruiz‐Heredia, Yanira, additional, Martínez‐Cuadrón, David, additional, Barragán, Eva, additional, Martinez‐Sanchez, Pilar, additional, Linares, María, additional, Rapado, Inmaculada, additional, Perez‐Oteyza, Jaime, additional, Magro, Elena, additional, Herrera, Pilar, additional, Rojas, José Luis, additional, Gorrochategui, Julián, additional, Villoria, Jesús, additional, Boluda, Blanca, additional, Sargas, Claudia, additional, Ballesteros, Joan, additional, Montesinos, Pau, additional, Martínez‐López, Joaquín, additional, and Ayala, Rosa, additional

Published
2020
Full Text
View/download PDF

5. What can we learn from studies comparing linezolid with vancomycin in neutropenic patients when vancomycin dosages are not optimized?

Author

Tattevin, Pierre, Camus, Christophe, Jaksic, Branimir, Martinelli, Giovanni, Perez-Oteyza, Jaime, Hartman, Charlotte S., Leonard, Linda B., and Tack, Kenneth J.

Subjects
Linezolid -- Dosage and administration, Vancomycin -- Dosage and administration, Drug therapy, Combination -- Economic aspects, Drug therapy, Combination -- Research, Neutropenia -- Drug therapy, Health, Health care industry
Published
2006

6. Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.

Author

Onecha, Esther, Ruiz‐Heredia, Yanira, Martínez‐Cuadrón, David, Barragán, Eva, Martinez‐Sanchez, Pilar, Linares, María, Rapado, Inmaculada, Perez‐Oteyza, Jaime, Magro, Elena, Herrera, Pilar, Rojas, José Luis, Gorrochategui, Julián, Villoria, Jesús, Boluda, Blanca, Sargas, Claudia, Ballesteros, Joan, Montesinos, Pau, Martínez‐López, Joaquín, and Ayala, Rosa

Subjects
ACUTE myeloid leukemia, FORECASTING, NUCLEOTIDE sequencing, CLINICAL drug trials, DRUG resistance
Abstract

Summary: Refractoriness to induction therapy and relapse after complete remission are the leading causes of death in patients with acute myeloid leukaemia (AML). This study focussed on the prediction of response to standard induction therapy and outcome of patients with AML using a combined strategy of mutational profiling by next‐generation sequencing (NGS, n = 190) and ex vivo PharmaFlow testing (n = 74) for the 10 most widely used drugs for AML induction therapy, in a cohort of adult patients uniformly treated according to Spanish PETHEMA guidelines. We identified an adverse mutational profile (EZH2, KMT2A, U2AF1 and/or TP53 mutations) that carries a greater risk of death [hazard ratio (HR): 3·29, P < 0·0001]. A high correlation was found between the ex vivo PharmaFlow results and clinical induction response (69%). Clinical correlation analysis showed that the pattern of multiresistance revealed by ex vivo PharmaFlow identified patients with a high risk of death (HR: 2·58). Patients with mutation status also ran a high risk (HR 4·19), and the risk was increased further in patients with both adverse profiles (HR 4·82). We have developed a new score based on NGS and ex vivo drug testing for AML patients that improves upon current prognostic risk stratification and allows clinicians to tailor treatments to minimise drug resistance. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

7. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

Author

Díez-Campelo, María, primary, Lorenzo, Jose I., additional, Itzykson, Raphael, additional, Rojas, Silvia M., additional, Berthon, Céline, additional, Luño, Elisa, additional, Beyne-Rauzy, Odile, additional, Perez-Oteyza, Jaime, additional, Vey, Norbert, additional, Bargay, Joan, additional, Park, Sophie, additional, Cedena, Teresa, additional, Bordessoule, Dominique, additional, Muñoz, Juan A., additional, Gyan, Emmanuel, additional, Such, Esperanza, additional, Visanica, Sorin, additional, López-Cadenas, Félix, additional, de Botton, Stéphane, additional, Hernández-Rivas, Jesús M., additional, Ame, Shanti, additional, Stamatoullas, Aspasia, additional, Delaunay, Jacques, additional, Salanoubat, Celia, additional, Isnard, Françoise, additional, Guieze, Romain, additional, Pérez Guallar, Joan, additional, Badiella, Llorenc, additional, Sanz, Guillermo, additional, Cañizo, Consuelo, additional, and Fenaux, Pierre, additional

Published
2018
Full Text
View/download PDF

8. Recommendations for the treatment of invasive fungal infection caused by filamentous fungi in the hematological patient

Author

Barberan, Jose, Mensa, Josep, Vallejo Llamas, Juan Carlos, Jarque Ramos, Isidro, Garcia Ruiz, Juan Carlos, Cabrera Marin, Jose Rafael, Baltasar Tello, Patricia, Battle Massana, Montse, Besalduch Vidal, Juan, Calvo Vinas, Jose Manuel, Capote Huelva, Francisco Javier, Carreras Pons, Enric, Diaz Mediavilla, Joaquin, Diaz Morfa, Miguel L., Escalante Barrigon, Fernando, Fernandez Avellan, Pascual, Garzon Lopez, Sebastian, Grande Garcia, Carlos, Hernandez Maraver, Dolores, La Guia, Ana Lopez, Lopez Jimenez, Javier, Martin Chacon, Eusebio, Olave Rubio, Mayte, Perez Oteyza, Jaime, Ramirez Ramirez, Gemma, Rojas Contreras, Rafael, Roman Barbero, Alejandro, Rovira Tarrats, Montserrat, Rubio Felix, Daniel, Sanchez Godoy, Pedro, Sanchez Salinas, Andres, Sanz Alonso, Miguel A., La Serna Torroba, Javier, Valcarcel Ferreiras, David, Vazquez Lopez, Lourdes, Aguado Garcia, Jose M., Azanza Perea, Jose Ramon, Canton Moreno, Rafael, Cisterna Cancer, Ramon, Fortun Abete, Jesus, Garcia Rodriguez, Julio, Gomez Gomez, Joaquin, Gomez Garcia La Pedrosa, Elia, Montejo Baranda, Jose Miguel, Javier Pernan Garcia, F., Ruiz Camps, Isabel, Miguel Sanz, and La Torre Cisneros, Julian

Subjects
Risk, Antifungal Agents, Leukemia, Mycoses, Myelodysplastic Syndromes, Humans, Hematologic Diseases
Abstract

Antifungal treatment in the hematological patient has reached a high complexity with the advent of new antifungals and diagnostic tests, which have resulted in different therapeutic strategies. The use of the most appropriate treatment in each case is essential in infections with such a high mortality. The availability of recommendations as those here reported based on the best evidence and developed by a large panel of 48 specialists aimed to answer when is indicated to treat and which agents should be used, considering different aspects of the patient (risk of fungal infection, clinical manifestations, galactomanann test, chest CT scan and previous prophylaxis) may help clinicians to improve the results.

Published
2011

9. Myelodysplastic Syndromes with I(17)(q10) and Prognostic Implications of Mutations of TP53 and SETBP1

Author

Adema, Vera, primary, Maria Jose, Larrayoz, additional, Maria Jose, Calasanz, additional, Palomo, Laura, additional, Patiño-Garcia, Ana, additional, Aguirre, Xabier, additional, Hernández-Rivas, Jesús María, additional, Lumbreras, Eva, additional, Buno, Ismael, additional, Martínez-Laperche, Carolina, additional, Mallo, Mar, additional, Garcia, Olga, additional, Gomez-Marzo, Paula, additional, Alvarez, Sara, additional, Blazquez, Beatriz, additional, Cervera, Jose, additional, Luño, Elisa, additional, Valiente, Alberto, additional, Vallespi, Teresa, additional, Vicente, Ana, additional, Arenillas, Leonor, additional, Collado, Rosa, additional, Perez-Oteyza, Jaime, additional, and Sole, Francesc, additional

Published
2014
Full Text
View/download PDF

10. What can we learn from studies comparing linezolid with vancomycin in neutropenic patients when vancomycin dosages are not optimized? Reply to Tattevin and Camus

Author

Jakšić, Branimir, Martinelli, Giovanni, Perez-Oteyza, Jaime, Hartmen, Charlotte, Leonard, Linda, and Tack, Kenneth

Subjects
fungi, Linezolid, food and beverages, heterocyclic compounds, biochemical phenomena, metabolism, and nutrition, bacterial infections and mycoses
Abstract

Reply to Tattevin and Camus:What can we learn from studies comparing linezolid with vancomycin in neutropenic patients when vancomycin dosages are not optimized

Published
2006

11. Is Azacitidine (AZA) Really Effective in High Risk MDS Patients with Chromosome 7 Abnormalities (Abn 7)? Results of a Retrospective Study From the GFM and GESMD Registries

Author

Díez-Campelo, María, primary, Itzykson, Raphael, additional, Rojas, Silvia M, additional, Berthon, Céline, additional, Luño, Elisa, additional, Beyne-Rauzy, Odile, additional, Perez-Oteyza, Jaime, additional, Vey, Norbert, additional, Bargay, Joan, additional, Park, Sophie, additional, Cedena, Teresa, additional, Bordessoule, Dominique, additional, Muñoz, Juan A, additional, Gyan, Emmanuel, additional, Such, Esperanza, additional, Visanica, Sorin, additional, Benlloch, Luis, additional, de Botton, Stéphane, additional, Hernández-Rivas, Jesús M, additional, Ame, Shanti, additional, Stamatoullas, Aspasia, additional, Delaunay, Jacques, additional, Salanoubat, Celia, additional, Isnard, Françoise, additional, Sanz, Guillermo, additional, Guieze, Romain, additional, Cañizo, Consuelo, additional, and Fenaux, Pierre, additional

Published
2012
Full Text
View/download PDF

12. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings

Author

Urbano-Ispizua, Alvaro, Rozman, Ciril, Pimentel, Pedro, Solano, Carlos, de la Rubia, Javier, Brunet, Salut, Pérez-Oteyza, Jaime, Ferrá, Christelle, Zuazu, Javier, Caballero, Dolores, Bargay, Joan, Carvalhais, Alzira, Dı́ez, Jose Luis, Espigado, Ildefonso, Alegre, Adrián, Rovira, Montserrat, Campilho, Fernando, Odriozola, Jesús, Sanz, Miguel Angel, Sierra, Jordi, Garcı́a-Conde, Javier, and Montserrat, Emili

Published
2002
Full Text
View/download PDF

13. Reply to Tattevin and Camus.

Author

Jaksic, Branimir, Martinelli, Giovanni, Perez-Oteyza, Jaime, Hartman, Charlotte S., Leonard, Linda B., and Tack, Kenneth J.

Subjects
LETTERS to the editor, NEUTROPENIA
Abstract

A response to a letter to the editor on the comparison between the efficacy of linezolid and vancomycin in neutropenic patients is presented.

Published
2006
Full Text
View/download PDF

14. Myelodysplastic Syndromes with I(17)(q10) and Prognostic Implications of Mutations of TP53and SETBP1

Author

Adema, Vera, Maria Jose, Larrayoz, Maria Jose, Calasanz, Palomo, Laura, Patiño-Garcia, Ana, Aguirre, Xabier, Hernández-Rivas, Jesús María, Lumbreras, Eva, Buno, Ismael, Martínez-Laperche, Carolina, Mallo, Mar, Garcia, Olga, Gomez-Marzo, Paula, Alvarez, Sara, Blazquez, Beatriz, Cervera, Jose, Luño, Elisa, Valiente, Alberto, Vallespi, Teresa, Vicente, Ana, Arenillas, Leonor, Collado, Rosa, Perez-Oteyza, Jaime, and Sole, Francesc

Abstract

INTRODUCTION

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results